Myeloproliferative Neoplasms

Findings from several large phase 3 studies along with continued development of emerging therapies promise to alter the treatment landscape for patients with myelodysplastic syndromes.

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.

Magenta Therapeutics has voluntarily paused enrollment for a phase 1/2 trial evaluating the antibody-drug conjugate MGTA-117 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome following the death of a patient.

The FDA has granted a priority review to the supplemental new drug application (sNDA) to avapritinib for the treatment of adult patients with indolent systemic mastocytosis.

First-line ruxolitinib plus pegylated interferon alpha 2a demonstrated durable spleen volume reduction in patients with myelofibrosis.

The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.

Jacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.

Significant and durable transfusion independence was achieved with imetelstat vs placebo in patients with lower-risk myelodysplastic syndromes who were relapsed, refractory, or ineligible for erythropoiesis-stimulating agents, meeting the primary and a key secondary end point of the phase 3 IMerge trial.

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

Low platelet counts were associated with a greater severity of disease-related symptoms compared with low hemoglobin in patients with myelofibrosis, according to findings from a retrospective analysis of the phase 3 PERSIST-1 and PAC203 trials.

Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

The European Medicines Agency has accepted a marketing authorization application for momelotinib as a treatment for patients with myelofibrosis.

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.